Skip navigation

EB Treatment Candidate BPM 31510 Granted Orphan Drug Designation in US

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BERG’s BPM 31510 (ubidecarenone), a treatment candidate for patients with epidermolysis bullosa (EB), the company announced.

This article goes on to discuss BERG’s commitment to the EB community and advancing much needed treatment options, while helping connect to the clinical trials for more information.

To read the full article, click here